Testing low-dose efavirenz treatment for Alzheimer’s disease: a phase 1b dosing, target-engagement and exploratory biomarker study.

Research Categorization
Researcher and Organization
Principal Investigator
Principal Investigator First Name
PHILIP
Principal Investigator Last Name
SCHELTENS
Awardee Organization
Contact PI Country
Project Detail
FY Overall Cost
$855,541
Funding Organization
Agency/Funding Organization
Funding Organization Country